Recently, it was found that in hepatocellular carcinoma (HCC) cells, GPAT3 upregulation reprograms lipid metabolism, and contributes to acquired resistance to sorafenib, the standard treatment for advanced HCC18. This evidence concerns the gene GPAT3 and hepatocellular carcinoma.